CompletedNCT00224510
Lamotrigine compared with placebo for bipolar depression in people taking lithium
About this title
A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium
Read the official source — NCT00224510Medication studyAges 18+Netherlands + SpainBipolarity
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Alkmaar and 30 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: August 2002
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Netherlands, Spain
- Age range
- Over 18 Years
- Official registry ID
- NCT00224510
- Official title
Show the full official title
A Mulitcentre, Double-blind, Randomised, Fixed-dose Evaluation of the Safety and Efficacy of Lamictal (Lamotrigine) Compared to Placebo as an add-on Therapy to Lithium or Another Mood Stabiliser in the Treatment of Bipolar Depression, Followed by Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Patients With Bipolar Disorder
Get this study by email
Recruitment & locations
CompletedAlkmaar, Netherlands · Almelo, Netherlands · Amersfoort, Netherlands
25 more locations
- Amsterdam, Netherlands
- Bennebroek, Netherlands
- Blaricum, Netherlands
- Delft, Netherlands
- Dordrecht, Netherlands
- Eindhoven, Netherlands
- Enschede, Netherlands
- Flushing, Netherlands
- Gouda, Netherlands
- Groningen, Netherlands
- Hoorn, Netherlands
- Leiden, Netherlands
- Nijmegen, Netherlands
- Raalte, Netherlands
- Retranchement, Netherlands
- Rosmalen, Netherlands
- The Hague, Netherlands
- Tilburg, Netherlands
- Utrecht, Netherlands
- Weert, Netherlands
- Zwolle, Netherlands
- Alava, Spain
- Barcelona, Spain
- Madrid, Spain
- Valencia, Spain
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including lamotrigine.
Who was this study for?
Listed age limits: from 18 years.
Want to explore more studies?
Explore studiesRelated studies
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...
A randomized controlled clinical trial for assessing the effectiveness of pharmacogenetic information obtained with NEUROFARMAGEN in the treatment of patients with mental disorders